Dematal

Dermata Therapeutics is a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate, DMT310, is a naturally derived, multi-component topical therapy being developed for the treatment of acne, rosacea, and psoriasis. DMT310 utilizes a unique mechanism of action involving mechanical exfoliation and the delivery of active biological compounds to the skin. Dermata is currently advancing its programs through late-stage clinical trials, aiming to provide new treatment options for patients with chronic inflammatory dermatological diseases.